Dyslipidaemia contributes to endothelial dysfunction and CVD (cardiovascular disease) in Type 2 diabetes mellitus. While statin therapy reduces CVD in these patients, residual risk remains high. Fenofibrate corrects atherogenic dyslipidaemia, but it is unclear whether adding fenofibrate to statin therapy lowers CVD risk. We investigated whether fenofibrate improves endothelial dysfunction in statin-treated Type 2 diabetic patients. In a cross-over study, 15 statin-treated Type 2 diabetic patients, with LDL (low-density lipoprotein)-cholesterol <2.6 mmol/l and endothelial dysfunction [brachial artery FMD (flow-mediated dilatation) <6.0%] were randomized, doubleblind, to fenofibrate 145 mg/day or matching placebo for 12 weeks, with 4 weeks washout between treatment periods. Brachial artery FMD and endothelium-independent NMD (nitrate-mediated dilatation) were measured by ultrasonography at the start and end of each treatment period. PIFBF (post-ischaemic forearm blood flow), a measure of microcirculatory endothelial function, and serum lipids, lipoproteins and apo (apolipoprotein) concentrations were also measured. Compared with placebo, fenofibrate increased FMD (mean absolute 2.1 + − 0.6 compared with −0.3 + − 0.6 %, P = 0.04), but did not alter NMD (P = 0.75). Fenofibrate also increased maximal PIFBF {median 3.5 [IQR (interquartile range) 5.8] compared with 0.3 (2.1) ml/100 ml/min, P = 0.001} and flow debt repayment [median 1.0 (IQR 3.5) compared with −1.5 (3.0) ml/100 ml, P = 0.01]. Fenofibrate lowered serum cholesterol, triacylgycerols (triglycerides), LDL-cholesterol, apoB-100 and apoC-III (P 0.03), but did not alter HDL (high-density lipoprotein)-cholesterol or apoA-I. Improvement in FMD was inversely associated with on-treatment LDL-cholesterol (r = −0.61, P = 0.02) and apoB-100 (r = −0.54, P = 0.04) concentrations. Fenofibrate improves endothelial dysfunction in statin-treated Type 2 diabetic patients. This may relate partly to enhanced reduction in LDLcholesterol and apoB-100 concentrations.
INTRODUCTION
In Type 2 diabetes, increased CVD (cardiovascular disease) risk is causally related to atherogenic dyslipidaemia that is characterized by elevated plasma concentrations of triacylgycerols and small dense LDL (low-density lipoprotein) particles and reduced HDL (high-density lipoprotein)-cholesterol. Statin therapy decreases CVD events in Type 2 diabetes [1] , but statins principally reduce LDL particle concentrations. A significant proportion of statin-treated patients remain at high residual risk of cardiovascular disease [2, 3] . This could be due to inadequate management of other aspects of diabetic dyslipidaemia.
Fenofibrate, a PPAR (peroxisome proliferatoractivated receptor)-α agonist, corrects atherogenic dyslipidaemia by lowering plasma triacylgycerols and consequently modifying LDL and HDL particle morphology. Fenofibrate appears particularly efficacious in reducing CVD risk in Type 2 diabetic patients with dyslipidaemia [4] . However, it remains unclear whether adding fenofibrate to statin therapy yields additional cardiovascular benefit in these patients [5] .
Endothelial dysfunction is an early indicator of diabetic vascular disease, and its presence predicts CVD events [6] . Fenofibrate improves brachial artery FMD (flow-mediated dilatation), an index of endotheliumdependent vasorelaxation, in subjects with and without Type 2 diabetes in the absence of statin therapy [7, 8] . Fenofibrate when co-administered with CoQ 10 (coenzyme Q 10 ) also improves forearm microcirculatory function and BP (blood pressure) in Type 2 diabetic patients [9] . Moreover, fenofibrate can improve brachial artery FMD in statin-treated non-diabetic subjects with dyslipidaemia [10] . Whether this applies to Type 2 diabetic patients remains to be demonstrated.
The primary aim of our study was to test the hypothesis that, in statin-treated Type 2 diabetic patients with endothelial dysfunction, fenofibrate would improve endothelial function in both the brachial artery and forearm resistance arterioles. We also investigated whether fenofibrate's effects on endothelial function in the peripheral circulation might be related to modification of residual dyslipidaemia.
MATERIALS AND METHODS

Subjects
We recruited patients aged 40-79 years with Type 2 diabetes (by American Diabetes Association criteria) [11] , who had been on stable dose statin therapy for at least 6 weeks. Inclusion criteria were serum LDL-cholesterol <2.6 mmol/l and endothelial dysfunction (defined as brachial artery FMD <6.0 % measured by ultrasonography). Exclusions included use of other lipid-regulating medication or antioxidant supplements, daytime insulin use, HbA 1c (haemoglobin A 1c ) >9.0 %, supine BP >150/90 mmHg, serum triacylgycerols 4.5 mmol/l, current tobacco use, ethanol intake >210 g/week, serum creatinine >150 umol/l, CK (creatine kinase) or ALT (alanine aminotransferase) >3 times the upper reference range limit, abnormal thyroid function, anaemia and cardiovascular event within 6 months prior to recruitment.
Study design
Eligible participants were randomized, double-blind to treatment with fenofibrate 145 mg/day (Laboratoires Fournier) or matching placebo for 12 weeks. Following a washout period of 4 weeks, participants crossed over to the alternate treatment for a further 12 weeks. Endothelial function of the peripheral circulation and other clinical variables were assessed at the start and end of each treatment period. The Royal Perth Hospital Ethics Committee approved the study, and all procedures were carried out in accordance with the Declaration of Helsinki. All participants gave written informed consent.
Clinical measurements
Resting supine BP was measured using a Dinamap recorder (Model 1846SX; Critikon). Height and weight were measured, and BMI (body mass index) was calculated. Fasting bloods were drawn at the start and end of each treatment period for measurement of serum lipids, apo (apolipoproteins), creatinine, ALT, CK, glucose and HbA 1c . Creatinine, ALT and CK were also measured at the midpoint of each treatment period.
Brachial artery ultrasonography
Brachial artery FMD was measured by ultrasonography, as previously described [12] . Briefly, the brachial artery was imaged using a 12-MHz transducer connected to an Acuson Aspen ultrasound system (Siemens Medical Solutions USA Inc.). After measuring baseline arterial diameter, a pneumatic tourniquet was placed around the forearm and rapidly inflated to 200 mmHg for 5 min to induce local ischaemia. During the period of reactive hyperaemia following cuff release, scanning was continued for 4 min to assess FMD. Estimates of brachial artery blood flow rates at rest and after cuff deflation were derived from pulse wave Doppler flow velocities. NMD (nitrate-mediated dilatation) (endothelium-independent) was also measured following sublingual administration of glyceryl trinitrate 400 μg. Ultrasound images were stored digitally for subsequent analysis using a semiautomated edge-detection software system. Responses to the vasodilatory stimuli were calculated as maximal percentage change in brachial artery diameter compared with baseline. All scans were preformed by the same skilled operator according to published guidelines [13] . Images were assessed by two independent observers who were blinded to treatment allocation. The analytical CVs (coefficients of variation) for our computerized technique are 6.7 % (intraobserver) and 14.7 % (within-subject) [14] . All scans were of good quality and were used in the analysis.
Forearm blood flow
Vascular reactivity of forearm resistance arterioles was measured using venous occlusion strain-gauge plethysmography (Hokanson), as previously described [15] . Briefly, after resting for 10 min, the subject's supine BP was measured by Dinamap recorder at 1 min intervals for 5 min. BFBF (basal forearm blood flow) was measured for five plethysmographic cycles, after which an arterial occlusion cuff was applied to the left upper arm and inflated to 40 mmHg above systolic BP for 4 min. After cuff release, PIFBF (post-ischaemic forearm blood flow) was measured for 4 min (15 plethysmographic cycles), from which maximal PIFBF was derived. Data were acquired on a Macintosh PC using Chart for Windows version 3.5 (AD Instruments). BFBF and PIFBF were calculated by selection of the steepest gradient of each flow curve and expressed as ml/100 ml forearm/min. Intraobserver CV for PIFBF was <5 % [15] . Flow debt repayment was derived from the hyperaemic blood flow curve using nonlinear regression analysis (GraphPad Prism, version 4.02, GraphPad Software, Inc). Basal and minimum FVR (forearm vascular resistance) were calculated using the formulae: basal FVR = MAP (mean arterial pressure)/mean BFBF [16] , and minimum FVR = MAP/maximal PIFBF [16, 17] .
Laboratory methods
Total cholesterol, triacylgycerols and HDL-cholesterol were determined by standard enzymatic methods (Hitachi; Roche Diagnostics) and LDL-cholesterol was calculated using the Friedewald formula. ApoA-I and apoB-100 were measured by immunonephelometry (Dade-Behring BNII), and apoC-III was measured by immunoturbimetry (Wako Pure Chemical Industries). HbA 1c was measured using HPLC (VARIANT II; BioRad Laboratories). Serum glucose, creatinine, ALT and CK were measured using Roche Diagnostics reagents and a HITACHI 917 analyser.
Statistical methods
Data were analysed using SPSS 15.0 and SAS 9.1 with logarithmic transformation of variables where appropriate. Data for log-transformed variables are shown as median [IQR (interquartile range)]. Treatment effects were compared using a mixed-effects model with adjustment for baseline, treatment sequence and period. Given the low power of tests for carry-over effects and their alias with other effects, a washout period was used to control for carry-over effects. Tests for carry-over were also performed but failed to reach significance at α = 0.1. Correlations are provided to indicate the strength of linear associations between change in FMD and ontreatment serum lipid and apo concentrations. Using a cross-over study design, an estimated sample size of 15 subjects was required to detect a difference in treatment effect of 2 % absolute change in FMD with at least 80 % power at α = 0.05.
RESULTS
Baseline clinical characteristics
Fifteen of 34 diabetic patients screened (44 %) were found to have endothelial dysfunction of the brachial artery (FMD <6.0 %) and were enrolled in the study. The study participants had significantly lower brachial artery FMD than those excluded (mean 3.5 + − 0.5 compared with 6.4 + − 0.8 %, P = 0.004) and non-diabetic controls (n = 16) studied using similar methods (mean 3.5 + − 0.5 compared with 6.4 + − 1.0 %, P = 0.01) [12] . Table 1 shows the baseline clinical characteristics of the randomized participants. They were typically middle-aged and overweight, with satisfactory control of glycaemia, BP and serum lipids. All were treated to an LDL-cholesterol level <2.6 mmol/l (mean 2.0 + − 0.4 mmol/l); atorvastatin was the most commonly used statin (47 %). Median duration of diabetes was 7 years and 73 % of patients were taking antihyperglycaemic medications. Two-thirds of subjects had a history of hypertension, one-third had CVD and one patient each had microalbuminuria and sensory neuropathy. Half the participants were taking aspirin or an ACEI (angiotensinconverting enzyme inhibitor); one quarter were on β-adrenergic-receptor-blocker therapy.
Changes in clinical and biochemical variables
Compared with placebo, fenofibrate was associated with significant reductions in serum total cholesterol, triacylgycerols, LDL-cholesterol, apoB-100 and apoC-III (P 0.03), but no change in HDL-cholesterol or apoA-I (P > 0.05). Fenofibrate had no significant treatment effects on supine BP, body weight or glycaemia (P > 0.05) ( Table 2 ).
All 15 subjects completed the study with no report of myopathic symptoms or other adverse events. Compared with placebo, fenofibrate was associated with a 17 % rise in serum creatinine (P < 0.001), but no significant change in CK or ALT (P > 0.05).
Changes in haemodynamic characteristics of the brachial artery and forearm resistance arterioles
Mean baseline brachial artery diameter was similar at each ultrasound assessment (Table 3A) . Following ischaemia, estimated brachial artery blood flow increased approximately 6-fold, with no significant difference between treatment groups. Compared with placebo, fenofibrate increased FMD (mean absolute 2.1 + − 0.6 compared with −0.3 + − 0.6 %, P = 0.04), but did not alter NMD (P = 0.75).
Basal forearm blood flow and vascular resistance were similar at each assessment (Table 3B) . Compared with placebo, fenofibrate increased maximal PIFBF [median 3.5 (IQR 5.8) compared with 0.3 (2.1) ml/100 ml/min, P = 0.001] and flow debt repayment [median 1.0 (IQR 3.5) compared with −1.5 (3.0) ml/100 ml, P = 0.01], and decreased minimum forearm vascular resistance [median −1.1 (IQR 1.0) compared with 0.0 (0.5) mmHg/ml/100 ml/min, P < 0.001].
The increase in brachial artery FMD on fenofibrate therapy was inversely associated with on-treatment serum LDL-cholesterol (r = −0.61, P = 0.02) and apoB-100 (r = −0.54, P = 0.04) concentrations, but not with change in LDL-cholesterol or apoB-100, nor with ontreatment serum triacylgycerols or HDL-cholesterol (Figure 1 ). Changes in PIFBF and flow debt repayment on fenofibrate treatment were not significantly associated with any of the lipid-related variables.
DISCUSSION
Our study shows that Type 2 diabetic patients with endothelial dysfunction (and hence increased CVD risk) despite treatment with a statin to a serum LDLcholesterol level <2.6 mmol/l benefit from additional therapy with fenofibrate in terms of improved conduit artery and microcirculatory endothelial function. The improvement in brachial artery FMD on fenofibrate treatment was related to on-treatment LDL-cholesterol and apoB-100 concentrations.
Endothelial dysfunction in diabetes is an antecedent of established vascular disease [6] . Statin therapy has been shown to improve endothelial dysfunction in diabetic subjects in some [18, 19] but not all [20] studies. Fenofibrate and related drugs appear to have a more consistent beneficial effect. We previously demonstrated that fenofibrate improved brachial artery FMD in statinnaïve Type 2 diabetic patients with dyslipidaemia [7] . Fenofibrate also improved forearm microcirculatory function in such patients when co-administered with CoQ 10 [9] . Moreover, we recently demonstrated that fenofibrate and CoQ 10 independently and interactively lowered 24-h ambulatory BP [21] , consistent with their beneficial effects on endothelial function in resistance arterioles. Ciprofibrate and gemfibrozil (other fibric acid derivatives) have been shown to improve brachial artery FMD in Type 2 diabetic subjects in fasting and postprandial studies [22, 23] . In non-diabetic subjects with mixed hyperlipidaemia, fenofibrate has been shown to improve brachial artery FMD [8] . Combination treatment with atorvastatin and fenofibrate has also been shown to improve brachial artery FMD in similar subjects [10] . Our present study adds to these observations by demonstrating, for the first time, that fenofibrate improves endothelial function in at-risk statin-treated Type 2 diabetic patients.
Although short-term fenofibrate therapy may improve endothelial function [7, 8] , a substudy of the longer-term FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study showed no such treatment effect on carotid intima-media thickness, augmentation index or biomarkers of endothelial function [24] . However, the FIELD study subjects were mostly low risk (as evident from the low CVD event rate) and had not been selected for having endothelial dysfunction at baseline.
Mechanisms
Despite treatment with a statin to an optimal or nearoptimal LDL-cholesterol level and satisfactory control of BP and glycaemia, our study participants had persistent endothelial dysfunction and, by implication, perturbed NO biology. That fenofibrate significantly improved endothelium-dependent brachial artery FMD without change in endothelium-independent NMD, indicates improvement in the release and/or action of NO. The role of NO in maximal PIFBF is minimal, but contributes modestly during mid-to-late phase PIFBF [25] . Our finding of a significant improvement in forearm postischaemic flow debt repayment supports the notion of an NO-dependent mechanism, while increase in maximal PIFBF suggests that other factors, including regulation of ET-1 (endothelin-1) [26] , prostaglandins [27] , adenosine [28] , asymmetric dimethylarginine [29] and adiponectin [30] , may also contribute. Fenofibrate has been reported to enhance expression of eNOS (endothelial nitric oxide synthase) [31] and decrease expression of ET-1 [32] . Moreover, it can decrease vascular inflammation by depressing the activity of NF-κB (nuclear factor κB) and TNF-α (tumour necrosis factor α) activity [33] . The extent to which these mechanisms operate in the setting of statin therapy in Type 2 diabetes remains to be established. However, our regression analyses suggest that the improvement in brachial artery endothelial function on fenofibrate therapy involves, in part, enhanced reduction in serum LDL-cholesterol and apoB-100 concentrations, but not changes in triacylgycerols, HDL-cholesterol or apoA-I. This suggests that comparable improvements in endothelial function in our patients might have been achieved by further increasing the dose of the statin or adding ezetimibe to augment reductions in apoB-containing lipoproteins. The lack of correlation with HDL-cholesterol and HDL-apoA-I does not exclude the possibility that an improvement in HDL kinetics contributes to the improvement in arterial function. Moreover, as our outcome measures were assessed in the fasting state, we cannot exclude that the benefits of fenofibrate on endothelial dysfunction in diabetic patients in the setting of statin therapy is predominantly mediated by improvements in postprandial dyslipidaemia, and the possibility that it may be closely related to the reduction in apoC-III concentrations with fenofibrate. Our finding that the reduction in serum triacylgycerols was not associated with improvement in endothelial dysfunction suggests that increase in LDL particle size may be less important a mechanism than reduction in LDL particle number.
Study strengths and limitations
A potential limitation of our study was its inclusion of mostly male subjects, and it is uncertain whether there might be gender differences in treatment effects. Although our sample size was small, the cross-over trial design had adequate power to detect a 2 % absolute change in brachial artery FMD. Our 12-week intervention period was relatively short, but comparable to that of other trials that have demonstrated a therapeutic effect on endothelial function and CVD risk surrogates [7, 8] . However, long-term clinical endpoint studies are required to establish the full implications of our findings. The strengths of our study included selection of diabetic patients who, despite having satisfactory control of glycaemia, BP and serum lipids (on statin therapy), still had demonstrable endothelial dysfunction, a surrogate for residual CVD risk. We were also able to demonstrate improvement in endothelial function in two vascular beds, namely the brachial (conduit) artery and forearm resistance arterioles (microcirculation).
Clinical implications
The efficacy and safety of combination fenofibrate and statin therapy have been demonstrated in metabolic syndrome and Type 2 diabetic patients with combined hyperlipidaemia [10, 34] . We confirm the short-term efficacy, safety and tolerability of combination fenofibrate and statin therapy in Type 2 diabetic patients.
Therapeutic approaches for reducing residual CVD risk in statin-treated Type 2 diabetic patients include aggressive lowering of LDL-cholesterol with high-dose statin therapy (with or without ezetimibe) and correction of residual dyslipidaemia with fibrates, niacin or fish oils. Our results support the notion of benefit from adding fenofibrate to statin therapy: the 2 % absolute increase in brachial artery FMD achieved with additional fenofibrate treatment may translate into a further 15-30 % reduction in CVD risk [35] . This question may be more definitively addressed by the lipid arm of the ACCORD (Action to Control Cardiovascular Risk in Diabetes) study that is due to report shortly on whether adding fenofibrate to simvastatin over a treatment period of >4 years (mean 5.5 years) reduces CVD events in Type 2 diabetic patients compared with simvastatin therapy alone [5] .
